We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $363M
1-Year Est. Return 34.89%
This Fund
S&P 500
This Quarter Est. Return
+6.98%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$368M
AUM Growth
+$18.7M
Cap. Flow
+$14.9M
Cap. Flow %
4.04%
Top 10 Hldgs %
6.4%
Holding
553
New
113
Increased
199
Reduced
149
Closed
92

Top Buys

Rank Stock Value
1
EXPD icon
Expeditors International
EXPD
+$2.17M
2
INCY icon
Incyte
INCY
+$2.09M
3
WAT icon
Waters Corp
WAT
+$2.03M
4
AMAT icon
Applied Materials
AMAT
+$2.01M
5
LVS icon
Las Vegas Sands
LVS
+$2.01M

Top Sells

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$2.5M
2
EA
Electronic Arts
EA
+$2.43M
3
FOXA icon
Fox Class A
FOXA
+$2.05M
4
MS icon
Morgan Stanley
MS
+$2.04M
5
ATO icon
Atmos Energy
ATO
+$2.02M

Sector Composition

Rank Sector Weight
1 Healthcare 26.73%
2 Financials 22.73%
3 Technology 18.16%
4 Industrials 8.89%
5 Consumer Discretionary 7.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UPB
301
Upstream Bio Inc
UPB
$395M
$266K 0.07%
9,801
-42
-0.4% -$1.04K
NTLA icon
302
Intellia Therapeutics
NTLA
$1.67B
$265K 0.07%
29,493
+15,866
+116% +$218K
SMMT icon
303
Summit Therapeutics
SMMT
$11.1B
$265K 0.07%
15,141
+9,497
+168% +$179K
NRIX icon
304
Nurix Therapeutics
NRIX
$2.65B
$265K 0.07%
13,949
+4,435
+47% +$63.7K
INBX icon
305
Inhibrx
INBX
$1.3B
$264K 0.07%
+3,343
New +$228K
CLDX icon
306
Celldex Therapeutics
CLDX
$3.28B
$263K 0.07%
9,671
+4,079
+73% +$107K
NGNE icon
307
Neurogene
NGNE
$712M
$262K 0.07%
12,716
+7,138
+128% +$178K
MLYS icon
308
Mineralys Therapeutics
MLYS
$2.41B
$262K 0.07%
7,209
-417
-5% -$16.7K
STOK icon
309
Stoke Therapeutics
STOK
$2.11B
$261K 0.07%
8,214
-1,413
-15% -$42.5K
BHVN icon
310
Biohaven
BHVN
$2.21B
$260K 0.07%
23,072
+15,773
+216% +$195K
APGE icon
311
Apogee Therapeutics
APGE
$10.2B
$260K 0.07%
3,451
+733
+27% +$46.2K
DNTH icon
312
Dianthus Therapeutics
DNTH
$6.09B
$260K 0.07%
6,315
+416
+7% +$16.1K
SYRE icon
313
Spyre Therapeutics
SYRE
$9.25B
$259K 0.07%
7,913
+1,488
+23% +$38.9K
GHRS icon
314
GH Research
GHRS
$2.08B
$259K 0.07%
20,408
+11,539
+130% +$157K
VRDN icon
315
Viridian Therapeutics
VRDN
$2.67B
$256K 0.07%
8,233
+971
+13% +$26.6K
IMVT icon
316
Immunovant
IMVT
$8.25B
$256K 0.07%
10,069
+2,931
+41% +$65.4K
SION
317
Sionna Therapeutics
SION
$2.31B
$256K 0.07%
6,220
-478
-7% -$18.1K
GLUE icon
318
Monte Rosa Therapeutics
GLUE
$1.35B
$256K 0.07%
16,310
-6,818
-29% -$91.9K
NUVL
319
DELISTED
Nuvalent
NUVL
$255K 0.07%
2,538
+1,077
+74% +$106K
REPL icon
320
Replimune Group
REPL
$1.01B
$254K 0.07%
26,133
+14,622
+127% +$124K
BCYC
321
Bicycle Therapeutics
BCYC
$292M
$253K 0.07%
35,709
+22,615
+173% +$167K
TSHA icon
322
Taysha Gene Therapies
TSHA
$1.89B
$253K 0.07%
45,946
+3,008
+7% +$14.6K
VKTX icon
323
Viking Therapeutics
VKTX
$4B
$252K 0.07%
7,174
+3,192
+80% +$113K
CELC icon
324
Celcuity
CELC
$4.52B
$252K 0.07%
2,528
-6,531
-72% -$537K
TNGX icon
325
Tango Therapeutics
TNGX
$4.41B
$252K 0.07%
28,452
+5,920
+26% +$51K
11 12
13
14 15

Similar funds

RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
HS
HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

Virtus Investment Advisers's Q4 2025 Portfolio in Review

As of Q4 2025, Virtus Investment Advisers held 553 positions worth $368M, up 5.3% from $349M the previous quarter. Its ten largest holdings account for 6.4% of the portfolio.

Virtus Investment Advisers deployed $14.9M of net new capital in Q4 2025, opening 113 new positions and adding to 199 existing holdings. Its largest new stake was Expeditors International: 15,974 shares worth $2.38M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 17% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was VICI Properties, an estimated $1.66M trimmed.

  • Virtus Investment Advisers's largest Q4 2025 buy was Expeditors International: 15,974 shares worth $2.38M.
  • Virtus Investment Advisers added most to Incyte in Q4 2025, an estimated $2.09M increase.
  • Virtus Investment Advisers's biggest Q4 2025 reduction was VICI Properties, cutting an estimated $1.66M.
  • Virtus Investment Advisers fully exited Tesla in Q4 2025, selling an estimated $2.5M.
  • Virtus Investment Advisers's ten largest holdings make up 6.4% of its $368M portfolio in Q4 2025.
  • Virtus Investment Advisers opened 113 new positions and closed 92 in Q4 2025.
  • Virtus Investment Advisers's portfolio value rose 5.3% quarter-over-quarter to $368M.

Based on Virtus Investment Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.